Withus Pharmaceutical Co

Withus Pharmaceutical Co EBIT per Share

The EBIT per Share of Withus Pharmaceutical Co (330350.KQ) as of Nov 1, 2026 is 429.00 KRW. In the previous year, EBIT per Share was 413.31 KRW — a change of 3.80% (higher).

EBIT per Share

429.00KRW

YoY

3.80%

Last updated:

EBIT per Share of Withus Pharmaceutical Co is 2025 429.00 KRW. EBIT per Share of Withus Pharmaceutical Co was 2024 413.31 KRW. It decreases by 3.80% higher compared to the previous year.

The Withus Pharmaceutical Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
940.62 KRW
Jan 1, 2019
738.16 KRW
Jan 1, 2020
103.30 KRW
Jan 1, 2021
370.54 KRW
Jan 1, 2022
369.80 KRW
Jan 1, 2023
599.64 KRW
Jan 1, 2024
413.31 KRW
Jan 1, 2025
429.00 KRW
The Withus Pharmaceutical Co EBIT per Share history
YEAREBIT per ShareYoY
429.00KRW+3.80%
413.31KRW-31.07%
599.64KRW+62.15%
369.80KRW-0.20%
370.54KRW+258.70%
103.30KRW-86.01%
738.16KRW-21.52%
940.62KRW-3.03%
970.01KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Withus Pharmaceutical Co Stock analysis

What does Withus Pharmaceutical Co do? Withus Pharmaceutical Co Ltd is a pharmaceutical company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the manufacturing and distribution of prescription drugs, with its headquarters located in Seoul. As of the latest available information, Withus Pharmaceutical employs 191 full-time staff members. The company completed its initial public offering (IPO) on July 3, 2020, marking its entry into the public market. Its primary product categories include circulatory agents, musculoskeletal agents, digestive agents, antibiotics, and other prescription medications. Additionally, the company engages in contract manufacturing operations (CMO), providing manufacturing services for other pharmaceutical entities. Withus Pharmaceutical maintains a corporate website at https://www.withuspharm.com/mastart/mastart.php, which serves as a platform for company information and updates. The company operates in the pharmaceutical industry, contributing to the production and supply of essential medications in South Korea. Withus Pharmaceutical's business model integrates both direct product sales and contract manufacturing services, supporting its role in the broader healthcare ecosystem. The company's operations are centered around the development and delivery of prescription drugs, with a focus on key therapeutic areas such as cardiovascular health, musculoskeletal conditions, gastrointestinal treatments, and infectious disease management. The firm's activities are conducted under the regulatory framework of South Korea's pharmaceutical industry, adhering to local standards for drug manufacturing and distribution. Withus Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Withus Pharmaceutical Co stock

EBIT per Share of Withus Pharmaceutical Co is 429.00 KRW in 2025.

EBIT per Share of Withus Pharmaceutical Co changed from 413.31 KRW to 429.00 KRW, representing a 3.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Withus Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Withus Pharmaceutical Co

All Key Metrics — Withus Pharmaceutical Co